Modulation of Bax and mTOR for Cancer Therapeutics
Rui Li(Hunan Academy of Agricultural Sciences), Xingming Deng(Emory University), Guojing Zhang(Emory University), Jia Zhou(Io Therapeutics (United States)), Gabriel Sica(Emory University), Walter J. Curran(Piedmont Cancer Institute), Andrew T. Magis(Institute for Systems Biology), Melissa Gilbert‐Ross(Emory Healthcare), Dongkyoo Park(Central South University), Fadlo R. Khuri(American University of Beirut Medical Center), Adam I. Marcus(Emory Healthcare), Wei Zhou(Emory University), Chunyong Ding(Shanghai Jiao Tong University), Haian Fu(Emory University), Zhuo G. Chen(Emory University), Suresh S. Ramalingam(Emory University), Jun Zhang(OSF HealthCare), Guo Chen(Jinan University), Maohua Xie(Central South University), Ye Ding(Tianjin University), Dong M. Shin(Emory University), Shi-Yong Sun(Emory University), Taofeek K. Owonikoko(UPMC Hillman Cancer Center)
Cited by 35
Related Papers
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k
Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial
|The Lancet|2004|2.4k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k